-
我国新生儿出生缺陷的比例较高,占总出生人口的4%~6%,其中染色体病是导致新生儿先天缺陷及死亡的主要原因[1]。唐氏综合征(Down′s syndrome,DS)又称21-三体综合征,是较为常见的染色体异常疾病,DS胎儿流产率高,有明显的智力低下及心血管畸形等临床表现,DS严重影响了胎儿健康,给患儿家庭带来不利影响[2-3]。因此对于DS的产前筛查至关重要。在孕早期及中期采用超声行胎儿颈部半透明层厚度(nuchal translucecy,NT)检测DS的方法在我国逐渐得到重视,NT指胎儿皮肤与背侧软组织直接的厚度,被认为是DS筛查的有效指标[4-5]。血浆相关蛋白A(PAPP-A)是目前早孕期DS筛查的有效血清学指标,解整合素-金属蛋白酶12(ADAM12)是定位于细胞膜表面的糖蛋白,在细胞分化、黏附、融合等过程中具有重要作用,其在妊娠母体内具有较好的特异性,可作为孕期胎儿染色体异常的有效标志物。本文旨在探讨NT结合血清PAPP-A、ADAM12检测在DS筛查中的应用价值,现作报道。
-
NT检测高危孕妇15例,血清PAPP-A检测高危孕妇19例,血清ADAM12检测高危孕妇20例,NT联合血清PAPP-A及ADAM12检测高危孕妇6例,其中NT检测漏诊2例,PAPP-A检测漏诊2例,血清ADAM12检测漏诊1例,联合检测无漏诊。
-
NT、血清PAPP-A及ADAM12单独检测的敏感度、准确度、准确度、阳性预测值及阴性预测值比较差异无统计学意义(P>0.05)。NT联合PAPP-A及ADAM12诊断的敏感度、准确度、特异度、阴性预测值、阳性预测值显著高于NT、血清PAPP-A、ADAM12单独检测(P < 0.05)(见表 1)。
检测方法 灵敏度 特异度 符合率 阳性预测值 阴性预测值 NT 66.67(4/6) 96.53(306/317) 95.98(310/323) 26.67(4/15) 99.35(306/308) PAPP-A 66.67(4/6) 95.90(304/317) 95.36(308/323) 21.05(4/19) 99.35(304/306) ADAM12 83.33(5/6) 95.27(302/317) 95.05(307/323) 25.00(5/20) 99.67(302/303) 联合检测 100.00(6/6)*△# 100.00(317/317)*△# 100.00(323/323)*△# 100.00(6/6)*△# 100.00(317/317)*△# χ2 3.78 14.26 15.62 3.91 14.93 P < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 注:与NT比较*P < 0.05;与PAPP-A比较△P < 0.05;与ADAM12比较#P < 0.05 表 1 单项检测与联合检测对DS的诊断结果比较(%)
-
NT、血清PAPP-A及ADAM12单独检测及联合检测的ROC曲线下面积分别为0.802、0.729、0.762、0.905,联合检测的ROC曲线面积显著高于NT、血清PAPP-A及ADAM12单独检测(P < 0.05)(见图 1)。
胎儿NT联合血清PAPP-A、ADAM12检测在唐氏综合征产前筛查中的临床应用
The appplication value of the combination detection of fetal NT and serum PAPP-A, ADAM12 in the prenatal screening of DS
-
摘要:
目的分析胎儿颈部半透明层厚度(NT)超声联合血浆相关蛋白A(PAPP-A)、解整合素-金属蛋白酶12(ADAM12)检测在唐氏综合征(DS)产前筛查的临床价值。 方法选取323名接受早期孕检的孕妇作为研究对象,所有产妇于孕11~14周行B超检查NT,并在孕15~21周行血清PAPP-A、ADAM12检测,比较NT、PAPP-A、ADAM12单项检测及联合检测DS的结果。 结果NT检测结果显示高危孕妇15例,血清PAPP-A检测高危孕妇19例,血清ADAM12检测高危孕妇20例,NT联合血清PAPP-A及ADAM12检测高危孕妇6例,其中NT检测漏诊2例,PAPP-A检测漏诊2例,血清ADAM12检测漏诊1例。NT联合PAPP-A及ADAM12诊断的敏感度、准确度、特异度、阴性预测值、阳性预测值显著高于NT、血清PAPP-A、ADAM12单独检测(P < 0.05)。NT、血清PAPP-A及ADAM12单独检测及联合检测的ROC曲线下面积分别为0.802、0.729、0.762、0.905,联合检测的ROC曲线面积高于NT、血清PAPP-A及ADAM12单独检测(P < 0.05)。 结论采用NT联合血清PAPP-A、ADAM12检测产前筛查DS可明显提升其检出率,具有很好的临床应用价值。 -
关键词:
- 唐氏综合征 /
- 颈部半透明层厚度 /
- 血浆相关蛋白A /
- 解整合素-金属蛋白酶12
Abstract:ObjectiveTo explore of the clinical value of transthoracic thickness(NT)ultrasound combined with levels of plasma associated protein A(PAPP-A)and disintegrin-metalloproteinase 12(ADAM12)in the prenatal screening of Down's syndrome(DS). MethodsThree hundred and twenty-three women with pregnancy 11 to 14 weeks were examined using B-ultrasound, and the serum levels of PAPP-A and ADAM12 at 15 to 21 weeks of gestation were measured.The results between the single detection of NT, PAPP-A and ADAM12, and combination detection of NT, PAPP-A and ADAM12 in the diagnsois of DS were compared. ResultsFifteen, 19, 20 and 6 high-risk pregnant women were identified using the single detection of NT, PAPP-A and ADAM12, and combination detection of NT, PAPP-A and ADAM12, respectively.Two, 2 and 1 cases were missed diagnosis using the detetcion of NT, PAPP-A and ADAM12, respectively.The sensitivity, accuracy, specificity, negative predictive value and positive predictive value of the combination detection of NT, PAPP-A and ADAM12 were significantly higher than those of single of NT, serum PAPP-A and ADAM12(P < 0.05).The areas under the ROC of the single detection of NT, serum PAPP-A and ADAM12, and combination detection were 0.802, 0.729, 0.762 and 0.905, respectively.The ROC curve area of the combination detection was significantly higher than that of single detetcion of NT, serum PAPP-A and ADAM12(P < 0.05). ConclusionsThe combination detection of NT, serum PAPP-A and ADAM12 can significantly improve the detection rate of DS, and has good clinical value. -
表 1 单项检测与联合检测对DS的诊断结果比较(%)
检测方法 灵敏度 特异度 符合率 阳性预测值 阴性预测值 NT 66.67(4/6) 96.53(306/317) 95.98(310/323) 26.67(4/15) 99.35(306/308) PAPP-A 66.67(4/6) 95.90(304/317) 95.36(308/323) 21.05(4/19) 99.35(304/306) ADAM12 83.33(5/6) 95.27(302/317) 95.05(307/323) 25.00(5/20) 99.67(302/303) 联合检测 100.00(6/6)*△# 100.00(317/317)*△# 100.00(323/323)*△# 100.00(6/6)*△# 100.00(317/317)*△# χ2 3.78 14.26 15.62 3.91 14.93 P < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 注:与NT比较*P < 0.05;与PAPP-A比较△P < 0.05;与ADAM12比较#P < 0.05 -
[1] 徐婷, 刘彤. 唐氏综合征产前筛查研究进展[J]. 中国实用妇科与产科杂志, 2019, 35(2): 247. [2] 郭延清. 唐氏综合征及孕中期血清学筛查探讨[J]. 生物学教学, 2015, 40(8): 63. [3] 杨岚, 唐叶, 郭彩琴, 等. 产前诊断与血清学筛查在高龄孕妇唐氏综合征中的应用比较[J]. 南京医科大学学报(自然科学版), 2015, 35(3): 414. [4] PITKANENS, LAITINEN P, YLA-OUTINEN A, et al. Extremely large nuchal translucency measurement predicts adverse pregnancy outcome[J]. J Obstet Gynaecol, 2015, 35(1): 22. doi: 10.3109/01443615.2014.935713 [5] IUCULANO A, MURGIA F, PEDDES C, et ak. Metabolic characterization of amniotic fluids of fetuses with enlarged nuchal translucency[J]. J Perinat Med, 2019, 47(3): 311. doi: 10.1515/jpm-2018-0314 [6] 朱继红, 文珂. 胎儿鼻骨、颈项透明层厚度与母体血清学检测联合筛查唐氏综合征[J]. 中国现代医学杂志, 2016, 26(22): 50. [7] HOLZER I, HUSSLEIN PW, BETTELHEIM D, et al. Value of increased nuchal translucency in the era of noninvasive prenatal testing with cell-free DNA[J]. Int J Gynaecol Obstet, 2019, 145(3): 319. doi: 10.1002/ijgo.12808 [8] 朱继红, 陈英红, 文珂, 等. 超声测量胎儿颈项透明层厚度与孕中期母体血清学检测筛查唐氏综合征[J]. 重庆医学, 2015, 44(17): 2381. doi: 10.3969/j.issn.1671-8348.2015.17.027 [9] 杨苑香, 曾敏, 何倩云, 等. 189例唐氏综合征产前超声表现的临床特征[J]. 现代妇产科进展, 2018, 27(3): 182. [10] TANAC, WANAPIRAKC, SIRICHOTIYAKULS, et al. How to correct the impact of ethnicity on effectiveness of the second trimester maternal serum screen of fetal Down syndrome?[J]. J Matern Fetal Neonatal Med, 2019, 32(20): 3343. doi: 10.1080/14767058.2018.1463367 [11] CHAKSUWAT P, SIRICHOTIYAKUL S, LUEWAN S, et al. Evaluating the agreement of risk categorization for fetal down syndrome screening between ultrasound-based gestational age and menstrual-based gestational age by maternal serum markers[J]. Obstet Gynecol Int, 2018, 2018: 9687042. [12] 杨岚, 石锦平, 吴晓, 等. 早孕期血清PAPP-A检测联合中孕期血清AFP、free β-HCG、uE3检测对DS、ES的筛查效果[J]. 山东医药, 2017, 57(35): 18. [13] 汤瑾, 何松, 魏丽平. 血清PAPP-A、ADAM12-S、β-HCG及孕酮水平与胚胎停止发育的关系研究[J]. 临床和实验医学杂志, 2019, 18(7): 756. [14] 刘新, 汪越君, 迟建秀. B超检测NT联合血清PIGF、free β-hCG及ADAM12对唐氏综合征的预测价值[J]. 中国妇幼保健, 2018, 33(20): 4689. [15] ZIOLKOWSKA K, DYDOWICZ P, SOBKOWSKI M, et al. The clinical usefulness of biochemical(free β-hCg, PaPP-a)and ultrasound(nuchal translucency)parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy[J]. Ginekol Pol, 2019, 90(3): 161.